Know Cancer

forgot password

A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Phase 2
18 Years
Not Enrolling
Metastatic Breast Cancer

Thank you

Trial Information

A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Inclusion Criteria:

- Pathologically confirmed adenocarcinoma of the breast.

- Stage IV disease.

- Measurable disease (defined as the presence of at least one lesion that can be
accurately measured in at least one dimension with longest diameter greater or = 1.0
cm with spiral computed tomography (CT) scan).

- Patients must not be a candidate for Herceptin therapy (i.e., patients with HER-2
positive disease (gene amplification by fluorescence in situ hybridization (FISH) or
3 + overexpression by ICH) and patients with unknown HER-2 status are ineligible
unless the treating physicians has determined that Herceptin-based therapy would be
inappropriate or not indicated).

- For subjects with prior anthracycline exposure, normal cardiac function including a
baseline left ventricle ejection fraction >50% or above institution's lower limit of
normal and a normal electrocardiogram (ECG) (as assessed by the investigator).

- At least 2 weeks since radiotherapy, with full recovery. The measurable disease must
be completely outside the radiation portal or there must be pathologic proof of
progressive disease within the radiation portal.

- International Normalized Ratio (INR) < 1.5 and activated partial thromboplastin time
within normal limits (APTT WNL).

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

- Female > 18 years of age.

- Patients have the following blood counts at Baseline: absolute neutrophil count (ANC)
greater or equal to 1.5 x 10^9 cells/L; platelets greater or equal 100 x 10^9
cells/L; hemoglobin (Hgb) greater or equal to 9g/dL.

- Patients have the following blood chemistry levels at Baseline: aspartate
aminotransferase (AST or SGOT), alanine aminotransferase (ALT or SGPT) less than or
equal 2.5x upper limit of normal (ULN) range (less than or equal 5x ULN if patient
has known liver metastases); total bilirubin greater than or equal to ULN; creatinine
greater or equal to 1.5mg/dL.

- if female of childbearing potential, pregnancy test is negative within 72 hours of
first dose of study drug.

- if fertile, the patient agrees to use an effective method to avoid pregnancy for the
duration of the study.

- Informed consent has been obtained.

Exclusion Criteria:

- No prior chemotherapy for metastatic or locally recurrent disease is allowed.

- Prio neo-adjuvant chemotherapy is allowed, and patients must have recovered from the
acute toxicity of such therapies.

- if a taxane was part of the adjuvant regimen, at least 12 months must have
elapsed between the last dose of the taxane and the date of diagnosis of
metastatic disease.

- if a non-taxane-based adjuvant therapy was administered, at least six months
must have elapsed between the last dose of the non- taxane-containing
chemotherapy and the date of diagnosis of metastatic disease.

- Concurrent immunotherapy or hormonal therapy.

- Parenchymal brain metastases, including leptomeningeal involvement.

- Uncontrolled hypertension (defined as blood pressure of > 150/100 mmHg)

- NYHA Grade 2 or greater congestive heart failure

- History of coagulopathy, bleeding diathesis, therapeutic anticoagulation other than
low dose or chronic ASA greater than or equal to 325 mg per day. Low dose coumadin
for anticoagulation of venous access device or low dose molecular weight heparin
(LMWH)for deep vein thrombosis prophylaxis or low dose (325 mg or less) ASA
prophylaxis are allowed, but are best avoided if the treating physician feels it is
safe to do so.

- Urine protein:creatinine ratio less than or equal to 1.0 at screening.

- No history of cerebrovascular accident within six months of study entry.

- Active symptomatic peripheral vascular disease (e.g. aortic aneurysm, claudication)
within six months of study entry.

- Uncontrolled or severe cardiovascular disease including myocardial infarction or
unstable angina within six months of study entry.

- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
process within six months of study entry.

- No serious non-healing wound, ulcer, or bone fracture

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to first dose, or anticipation of need for major surgical procedure during the
course of the study. No minor surgical procedure within seven days of study entry.
Serious intercurrent medical or psychiatric illness, including serious active

- History of other malignancy within the last 5 years which could affect the diagnosis
or assessment of breast cancer.

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study.

- Pregnant or nursing women.

- Patients with current sensory neuropathy of > Grade 1 will be excluded.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Participants With At Least One Treatment-Emergent Adverse Event (TEAE)

Outcome Description:

Count of study participants who had at least one treatment-emergent adverse event (TEAE) defined as any adverse event that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug.

Outcome Time Frame:

up to 25 months

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

June 2006

Completion Date:

February 2011

Related Keywords:

  • Metastatic Breast Cancer
  • Metastatic breast cancer, Abraxane, Bevacizumab
  • Breast Neoplasms



Hinsdale, Illinois  60521
Miami, Florida  33176
Columbia, Missouri  65203
Albany, New York  12208
Austin, Texas  78705
Seattle, Washington  98195
McLean, Virginia  22101
Baltimore, Maryland  21287
Indianapolis, Indiana